STOCK TITAN
  1. Home
  2. Sec-filings
  3. AKRO
  4. [Form 4] Akero Therapeutics, Inc. Insider Trading Activity

Akero (AKRO) insider buys 52,212 shares at $0.615; CEO holdings update

Filing Impact
(Neutral)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

Andrew Cheng, who serves as President and CEO and a director of Akero Therapeutics, Inc. (AKRO), reported a change in beneficial ownership dated 10/08/2025. The filing shows an acquisition of 52,212 shares/options at a price of $0.615 per share, and after the reported transaction Mr. Cheng beneficially owns 526,114 shares. The document also discloses a derivative entry for 52,212 stock options with the same exercise price; the filer notes these options are vested and currently exercisable. The Form is signed by an attorney-in-fact on 10/09/2025.

Positive

  • None.

Negative

  • None.
Insider Cheng Andrew
Role President and CEO
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 52,212 $0.00 --
Exercise Common Stock 52,212 $0.615 $32K
Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 526,114 shares (Direct)
Footnotes (1)
  1. [object Object]
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cheng Andrew
(Last) (First) (Middle)
C/O AKERO THERAPEUTICS, INC.
601 GATEWAY BOULEVARD, SUITE 350
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Akero Therapeutics, Inc. [ AKRO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
10/08/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/08/2025 M 52,212 A $0.615 526,114 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $0.615 10/08/2025 M 52,212 (1) 09/07/2028 Common Stock 52,212 $0 0 D
Explanation of Responses:
1. The options are vested and currently exercisable.
/s/ Jonathan Young, Attorney-in-Fact 10/09/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What transaction did AKRO insider Andrew Cheng report on the Form 4?

The Form 4 reports an acquisition of 52,212 shares/options with an effective date of 10/08/2025 at a price of $0.615 per share.

How many AKRO shares does Andrew Cheng beneficially own after the transaction?

Following the reported transaction, Andrew Cheng beneficially owns 526,114 shares.

Are the reported stock options exercisable?

Yes. The filing states the reported options are vested and currently exercisable.

What is the exercise price and expiration/exercisable info for the derivative reported?

The stock option shows an exercise price of $0.615 and a date listed as 09/07/2028 in the table for exercisable/expiration information.

Who signed the Form 4 and when?

The Form 4 is signed by Jonathan Young, Attorney-in-Fact on 10/09/2025.